Five Prime Therapeutics Inc (FPRX.OQ)
18 Sep 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||2018||Executive Chairman of the Board|
|48||2018||President, Chief Executive Officer, Chief Operating Officer, Director|
|48||2018||Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer|
|54||2018||Executive Vice President, Chief Scientific Officer|
|57||2016||Senior Vice President, Development Sciences|
- BRIEF-Five Prime Therapeutics Announces Collaboration With Roche
- BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63
- BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO
- BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial
- BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics